Seventeen years ago, Philip Segal opted for active surveillance for Gleason 6 prostate cancer, maintaining it for peace of mind. In contrast, Bruno Barrey transitioned to radiation therapy after a follow-up biopsy revealed more advanced lesions. The approach's duration varies based on multiple factors, including cancer volume, PSA levels, and geographic location. Dropout rates from active surveillance have decreased with the adoption of MRI for staging, leading to more accurate diagnoses and treatment decisions. However, the decline in screening following recommendations against PSA testing may contribute to the rise in late-stage prostate cancer diagnoses. Urologists hold differing views on active surveillance, with some cautioning against it due to potential risks and others advocating for a partnership approach with patients.
다른 언어로
소스 콘텐츠 기반
www.medscape.com
핵심 통찰 요약
by Howard 게시일 www.medscape.com 01-05-2024
https://www.medscape.com/viewarticle/active-surveillance-low-risk-pca-sprint-or-marathon-2024a10000eq더 깊은 질문